### Editors’ note The Editors of the 5 journals of the American College of Rheumatology and European Alliance of Associations for Rheumatology have been reminded by this editorial that ACR and EULAR have jointly agreed on various classification criteria, definitions, recommendations, or points to consider, which do not always find reflection in manuscripts submitted to the journals. Consequently, in the future, the Editors will enforce the use of the products obtained in the course of joint ACR/EULAR or EULAR/ACR activities in all respective papers. For rheumatoid arthritis this would mean use of the ACR/EULAR or EULAR/ACR classification criteria, remission definitions, recommendations on what to report in clinical trials, and others, as pertinent. The same applies to other diseases. There are valid and important reasons that these activities have been undertaken by ACR and EULAR, and therefore, the conclusions of the various task forces, which have been endorsed by ACR and EULAR, should be respected by investigators and study administrators. This does not mean other methods could not be used in a study, but at the least, the reports should address the methods agreed on by the two organisations. Maintaining uniformity across major publications regarding rheumatoid arthritis remission or other definitions not only allows for more appropriate comparison across analyses, but also enhances readers' ability to interpret results. Author instructions across the five journals will more strongly reflect this requirement. Over the last 30 years, treatment for rheumatoid arthritis (RA) has improved dramatically. By the early 2000s, disease remission had become a realistic goal, although definitions of remission varied widely, making it difficult to compare treatment strategies and gauge how often remission occurred. In 2009, the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR) created a joint committee whose charge was to recommend a definition of remission. Members …

中文翻译：

---

重新检查类风湿性关节炎的缓解定义：考虑 28 关节疾病活动评分、C 反应蛋白水平和患者整体评估


### 编者注 这篇社论提醒美国风湿病学会和欧洲风湿病协会联盟的 5 种期刊的编辑，ACR 和 EULAR 已经就各种分类标准、定义、建议或需要考虑的要点达成了一致，这些并不总是反映在提交给期刊的手稿中。因此，将来，编辑将在所有相应论文中强制使用在 ACR/EULAR 或 EULAR/ACR 联合活动过程中获得的产品。对于类风湿性关节炎，这意味着使用 ACR/EULAR 或 EULAR/ACR 分类标准、缓解定义、临床试验中报告内容的建议等。这同样适用于其他疾病。ACR 和 EULAR 开展了这些活动是有正当和重要的理由的，因此，研究人员和研究管理人员应尊重已得到 ACR 和 EULAR 认可的各种工作组的结论。这并不意味着研究中不能使用其他方法，但至少，报告应该涉及两个组织商定的方法。在关于类风湿性关节炎缓解或其他定义的主要出版物中保持一致性，不仅可以在分析之间进行更适当的比较，还可以增强读者解释结果的能力。这五种期刊的作者说明将更强烈地反映这一要求。在过去的 30 年里，类风湿性关节炎 （RA） 的治疗有了显著改善。 到 2000 年代初，疾病缓解已成为一个现实的目标，尽管缓解的定义差异很大，因此很难比较治疗策略和衡量缓解发生的频率。2009 年，美国风湿病学会 （ACR） 和欧洲风湿病协会联盟 （EULAR） 成立了一个联合委员会，其职责是推荐缓解的定义。成员。。。